Order
Now

Reverse
dilation with
just 1-2 drops1

The only commercially available FDA-approved product that reverses pharmacologically-induced mydriasis.1

One single-patient-use vial should be dispensed for each patient, and it can be used to dose both eyes. Discard the single-patient-use vial immediately after use.1

PATIENTS AGED 12 YEARS AND OLDER1

1-2 drops

  • Instill 1 or 2 drops in each dilated eye following the completion of the ophthalmic examination or procedure
  • If 2 drops are instilled, the second drop should be administered 5 minutes after the first drop

PATIENTS AGED 3-11 YEARS1

1 drop

  • Instill 1 drop in each dilated eye following the completion of the ophthalmic examination or procedure

The efficacy of RYZUMVI® was similar for all age ranges, including pediatric subjects aged 3 to 17 years. Pediatric subjects aged 12 to 17 years (n=27) were treated in MIRA-2 and MIRA-3, and pediatric subjects aged 3 to 11 years (n=11) were treated in MIRA-4.1,2

As an eye care professional, the decision to use one or two drops of RYZUMVI is based on your discretion and judgment.

RYZUMVI (phentolamine ophthalmic solution) 0.75% packshot and vials

How RYZUMVI is supplied

RYZUMVI is a sterile, clear, and colorless topical ophthalmic solution and comes in a translucent, low-density polyethylene, single-patient-use vial (0.31 mL fill).1 Does not contain an antimicrobial preservative. Stable topical eye drops are available in a single-patient-use vial, with no mixing required.

PACKAGING1

  • Each carton contains 30 single-patient-use vials of RYZUMVI
  • One strip of 5 single-patient-use vials is packaged into a foil pouch, with 6 foil pouches in a carton

STORAGE & REFRIGERATION1

  • Store refrigerated at 2°C to 8°C (36°F to 46°F), not to exceed the expiration date printed on the carton and pouch
  • Protect from freezing
  • After opening the foil pouch, the product may be stored at 25°C (68°F to 77°F) and should be used within 14 days, not to exceed the expiration date printed on the vial
  • The single-patient-use vial once opened should be discarded immediately after use
Efficacy
& Safety
ORDER

INDICATIONS AND USAGE

RYZUMVI® (phentolamine ophthalmic solution) 0.75% is indicated for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.

See full ISI

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Uveitis: RYZUMVI is not recommended to be used in patients with active ocular inflammation (e.g., iritis).

Potential for Eye Injury or Contamination: To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface.

Use with Contact Lenses: Contact lens wearers should be advised to remove their lenses prior to the instillation of RYZUMVI and wait 10 minutes after dosing before reinserting their contact lenses.

Adverse Reactions

The most common adverse reactions that have been reported are instillation site discomfort (16%), conjunctival hyperemia (12%), and dysgeusia (6%).

Please see Full Prescribing Information

References: 1. RYZUMVI (phentolamine ophthalmic solution). Prescribing Information. Ocuphire. 2. Pepose JS, et al. Reversal of pharmacologically induced mydriasis with phentolamine ophthalmic solution. Ophthalmology. 2024. https://​doi.org/​10.1016/​j.ophtha.2024.09.010.